GrowLife, Inc. Announces Partner Agreement with Cannabis Technology Company to add Spectral Imagery to EZ-CLONE Systems
KIRKLAND, Wash. – June 2019 — GrowLife, Inc. (OTC: PHOT) (“GrowLife” or the “Company”), one of the nation’s most recognized indoor cultivation product and service providers, today announced that the Company has entered a partner agreement with award-winning cannabis technology Emerald Metrics, LLC to add proprietary technology to the Company’s cloning and propagation product line.
Through this agreement, GrowLife will add spectral imagery technology to the Company’s EZ-CLONE Pro commercial propagation system which gives plant cultivators invaluable insight into the health of the clones being grown in the system. Through this advanced software, cultivators are given advance notice about the clone’s health and any other issues that may be occurring with enough time to take action, well before any issues can be seen by the naked eye. Emerald Metrics has been granted a provisional patent for its Clone Imaging System, which is a unique hardware, software and mechanical solution for commercially viable clone health analysis through spectral imagery.
The agreement between the companies demonstrates the increased demand for technological advancements in cannabis and hemp cultivation and cloning. Cultivators need healthy and consistent clones in order to meet the volume the market is demanding, while keeping costs down and remaining profitable. This technology, paired with benefits of cloning and measurable advantages of using the EZ-CLONE systems, will enable cultivators to grow a greater number of viable plants than normally seen in table-top cloning or plants grown from seeds.
“We are constantly developing ways to add value to our renowned EZ-CLONE propagation systems and partnering with such an advanced and well-versed company such as Emerald Metrics seemed to be the perfect fit,” said GrowLife Executive Vice-President of Sales and Marketing Joseph Barnes. “We understand that cloning is the future of plant cultivation in both the cannabis and hemp industries. With both companies situated at the forefront of clone technology, this agreement will elevate the way both companies work and provide our customers with the increased level of technology and advancements they desire. It also enables them to produce healthier and more viable plants than any other technology on the market.”
There is a growing demand for healthy clones as the cannabis industry continues to expand. The global hemp market is expected to reach $5.7 billion across all markets by the year 2020, representing a three-year compound annual growth rate of 17.5%, according to The Global State of Hemp. Additionally, the ArcView Group recently released a report which examined the economic multiplier effects through which U.S. consumer spending on legal cannabis in 2021 of $20.8 billion would generate almost $40 billion in overall economic impact, 414,000 jobs, and more than $4 billion in tax receipts. (Source)
Learn more about Emerald Metrics by visiting their website, www.emeraldmetrics.com.
All stock recommendations and comments are the opinion of writer.
Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion.
All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.
You should be aware of the risks involved in stock investing, and you use the material contained herein at your own risk. Neither Market-Advisor.com nor any of its suppliers guarantee its accuracy or validity, nor are they responsible for any errors or omissions which may have occurred. The analysis, ratings, and/or recommendations made by Market-Advisor.com, and/or any of its suppliers do not provide, imply, or otherwise constitute a guarantee of performance.
Market-Advisor.com is comprised of reports, if any, embodying a unique system of stock analysis. Accuracy and completeness cannot be guaranteed. Users should be aware of the risks involved in stock investments. It should not be assumed that future results will be profitable or will equal past performance, real, indicated or implied.
The material on this website are provided for information purpose only. Market-Advisor.com does not accept liability for your use of the website. The website is provided on an “as is” and “as available” basis, without any representations, warranties or conditions of any ki